Novo Nordisk 2Q Net Profit Rose Despite Virus Disruption -- Earnings Review
August 06 2020 - 5:04AM
Dow Jones News
By Dominic Chopping
Novo Nordisk AS reported results for the second quarter on
Thursday. Here's what you need to know:
SALES: Sales were largely unchanged at 30.01 billion Danish
kroner ($4.77 billion) against a FactSet analyst forecast of
DKK30.73 billion. In the first quarter, patients in the U.S. and
Europe in particular stockpiled around DKK2 billion of medicines
during the coronavirus pandemic, but these patients destocked
during the second quarter. The Danish pharmaceutical company also
noted fewer patients initiating treatment as social-distancing
measures around the world were implemented.
NET PROFIT: Net profit rose to DKK10.63 billion from DKK9.6
billion a year earlier, beating the DKK10.13 billion forecast by
analysts in a FactSet poll.
WHAT WE WATCHED:
GLUCAGON-LIKE PEPTIDE-1: Sales of Novo Nordisk's glucagon-like
peptide-1 drugs, or GLP-1, for type 2 diabetes--Victoza, Ozempic
and Rybelsus--increased by 30% measured in Danish kroner and by 28%
at constant exchange rates to DKK19.4 billion. The sales increase
was positively impacted by Covid-19-related stocking, largely
offset by fewer patients initiating treatment. Sales of Ozempic
were DKK9.59 billion and Ozempic has now been launched in 43
countries. The GLP-1 segment's value share of the total diabetes
market has increased to 20.1% compared with 16.1% a year ago. Novo
Nordisk has a GLP-1 market share of 49.1%, up 2.7 percentage points
from a year before.
MARGINS: The gross margin in the second quarter of 2020 was
84.1% compared with 83.9% in the same period last year. The
increase of 0.2 percentage point of the gross margin reflects
positive product mix and a positive currency impact of 0.1
percentage point, partly countered by a negative impact from lower
realized prices in the U.S. The earnings before interest and taxes
margin rose to 46.1% against 44.8% in the second quarter of
2019.
GUIDANCE: For 2020, sales growth is still expected to be 3% to
6% at constant exchange rates, while reported sales growth is now
seen around two percentage points lower, from one percentage point
higher previously. Operating profit growth is now expected to be 2%
to 5% at constant exchange rates, from 1% to 5%, while reported
growth is now seen around three percentage points lower, from one
percentage point higher.
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
August 06, 2020 04:49 ET (08:49 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2023 to Apr 2024